Document Detail


Evaluating the incremental benefits of raising high-density lipoprotein cholesterol levels during lipid therapy after adjustment for the reductions in other blood lipid levels.
MedLine Citation:
PMID:  19858435     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: The role of high-density lipoprotein cholesterol (HDL-C) as a therapeutic target to prevent cardiovascular (CV) events remains unclear. We examined data from the Framingham Offspring Study from 1975 through 2003 to determine whether increases in HDL-C levels after lipid therapy was started were independently associated with a reduction in CV events. METHODS: Using Cox proportional-hazards regression, we evaluated the risk of a CV event associated with changes in blood lipid levels among individuals who started lipid therapy. The independent effect of HDL-C levels on future CV risk (average follow-up, 8 years) was estimated after adjustment for changes in low-density lipoprotein cholesterol, plasma triglycerides, and pretreatment blood lipid levels. Potential confounders (eg, smoking status, weight, and the use of beta-blockers) were then added to the model. Interactions between blood lipid levels were also explored. RESULTS: The change in HDL-C level was a strong independent risk factor for CV events (hazard ratio, 0.79 per 5-mg/dL increase; 95% confidence interval, 0.67-0.93) after adjustment for the other lipid changes associated with treatment. This relationship remained stable across a wide range of patient subgroups and did not appear to be associated with a specific drug class. An important interaction was observed: the lower the pretreatment low-density lipoprotein cholesterol level, the greater the impact of raising the HDL-C. CONCLUSIONS: Raising HDL-C levels with commonly used lipid medications appears to be an important determinant of the benefits associated with lipid therapy. These results support the further evaluation of therapies to raise HDL-C levels to prevent CV events.
Authors:
Steven A Grover; Mohammed Kaouache; Lawrence Joseph; Philip Barter; Jean Davignon
Related Documents :
21447765 - Low-residue diet in diverticular disease: putting an end to a myth.
21199735 - Role of ezetimibe in the prevention of cardiovascular disease: absence of evidence.
18657245 - Metabolic syndrome in bipolar disorder: a cross-sectional assessment of a health manage...
8017305 - Effects of heparin and cardiac catheterization on serum lipoprotein and triglyceride le...
12559475 - Effects of dietary carbohydrate on the development of obesity in heterozygous zucker rats.
7247985 - Selection of a strain of rats with spontaneous high cholesterolemia.
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Archives of internal medicine     Volume:  169     ISSN:  1538-3679     ISO Abbreviation:  Arch. Intern. Med.     Publication Date:  2009 Oct 
Date Detail:
Created Date:  2009-10-27     Completed Date:  2009-11-05     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0372440     Medline TA:  Arch Intern Med     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1775-80     Citation Subset:  AIM; IM    
Affiliation:
McGill Cardiovascular Health Improvement Program and Division of General Internal Medicine, McGill University Health Centre, Montreal, Quebec, Canada. steven.grover@mcgill.ca
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Aged, 80 and over
Anticholesteremic Agents / therapeutic use
Antilipemic Agents / therapeutic use*
Biological Markers / blood
Blood Pressure
Body Mass Index
Cardiovascular Diseases / blood,  prevention & control*
Cholesterol, HDL / blood*,  drug effects*
Cholesterol, LDL / blood
Comorbidity
Female
Humans
Kaplan-Meiers Estimate
Male
Middle Aged
Multivariate Analysis
Odds Ratio
Predictive Value of Tests
Proportional Hazards Models
Treatment Outcome
Triglycerides / blood
Chemical
Reg. No./Substance:
0/Anticholesteremic Agents; 0/Antilipemic Agents; 0/Biological Markers; 0/Cholesterol, HDL; 0/Cholesterol, LDL; 0/Triglycerides

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Sex differences in mortality after acute myocardial infarction: changes from 1994 to 2006.
Next Document:  Role of lifestyle and aging on the longitudinal change in cardiorespiratory fitness.